[M$5k subsidy] Will any FDA-approved GLP-1 agonists be withdrawn from the market for safety reasons by...
14
293
Ṁ2.4KṀ5.7K
2030
1D
1W
1M
ALL
36%
2030
28%
2029
21%
2028
20%
2027
16%
2025
16%
2026
Inspired by https://manifold.markets/AaronKaufman/will-any-fdaapproved-glp1-agonists and will use the same criteria:
GLP-1 agonists, such as semaglutide (ozempic/wegovy), tirzepatide (mounjaro), and dulaglutide (Trulicity), are becoming popular for weight loss and Type-2 diabetes treatment.
This market resolves positively if any approved GLP-1 agonists for either T2D or weight loss are withdrawn from the market due to safety reasons by the listed date. This applies either if the FDA mandates it or if the company withdraws the drug voluntarily.
Get Ṁ200 play money
More related questions
Related questions
Will aducanumab be withdrawn by the FDA by 2025?
46% chance
Will a GLP-1 agonist diabetes / weight loss drug be the top bestselling drug in 2025?
31% chance
Will any FDA-approved GLP-1 agonists be withdrawn from the market for safety reasons by 01/01/2025?
15% chance
Will GLP-1 agonists help stop or reverse the US obesity trend by end of 2027
73% chance
The FDA will warn about overuse or misuse of semaglutide (Ozempic, Wegovy and Rybelsus) before the end of 2024.
33% chance
Will one of the GLP agonist drugs (eg Semaglutude/Wegovy Tirzepatide/Mounjaro) have a black box warning by 2025
46% chance
Will Donald Trump ever take a GLP-1 agonist (eg Ozempic, Mounjaro, Wegovy, Zepbound, etc) for weight loss
58% chance
Will Ozempic / semaglutide be FDA-approved for Alzheimer's before 2030?
68% chance
Will 10 million Americans be on semaglutide (or yet-to-be-approved equally good or superior alternatives) by the end of 2030?
73% chance
Will an AI-designed drug get FDA approval by the end of 2025?
33% chance